Journals / İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi / 2022 / Cilt: 12 - Sayı: 1

Assessment of Intravenous Immunoglobulin Indications in Pediatric Intensive Care

Çocuk Yoğun Bakımda İntravenöz İmmünoglobulin Endikasyonlarının Değerlendirilmesi

Pages
6–12
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In offlabel diseases, especially in sepsis, the use of IVIg can be reduced with alternative treatments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Intravenous immunoglobulin (IVIg) is one of the most common biologic agents used in daily intensive care practice.
📊
Key Findings & Data:Method: The data of 116 patients who received IVIg treatment between 2014-2018 in a tertiary level pediatric intensive care unit were retrospectively evaluated.
💡
Conclusion & Impact:In offlabel diseases, especially in sepsis, the use of IVIg can be reduced with alternative treatments.
🔬Design:Research Article
📍Scope:2014-2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Intravenous immunoglobulin (IVIg) is one of the most common biologic agents used in daily intensive care practice. Our aim in this study was to evaluate IVIg indications and side effects in patients hospitalized in the pediatric intensive care unit. Method: The data of 116 patients who received IVIg treatment between 2014-2018 in a tertiary level pediatric intensive care unit were retrospectively evaluated. Results: The patient group with the highest use of IVIg was found to have sepsis. The highest dose was detected in patients with Steven Johnson syndrome and the highest total dose was detected in patients with secondary immunodeficiency. Use of IVIg in off-label diseases was found more than use by indication. Conclusion: IVIg is a life-saving treatment in selected patients and clinical conditions. In our study, the most common disease group in which IVIg was used and concomitant highest mortality was found to be sepsis. In offlabel diseases, especially in sepsis, the use of IVIg can be reduced with alternative treatments.

Özet

Amaç: İntravenöz immünoglobulin (İVİg), günlük yoğun bakım pratiğinde kullanılan en yaygın biyolojik ajanlardan biridir. Bu çalışmada amacımız çocuk yoğun bakım ünitesinde yatan hastalarda İVİg endikasyonlarını ve yan etkilerini değerlendirmektir. Yöntem: Üçüncü basamak çocuk yoğun bakım ünitesinde, 2014-2018 yılları arasında İVİg tedavisi almış 116 hastanın verileri retrospektif olarak değerlendirildi. Bulgular: İVİg kullanımının en fazla olduğu hasta grubu sepsis olarak bulundu. En yüksek doz steven johnson sendromu hastasında, toplam en yüksek doz ise sekonder immün yetmezlikli hastalarda saptandı. Endikasyon dışı hastalıklarda İVİg kullanımı, endikasyon ile kullanımdan daha fazla saptandı. Sonuç: İVİg, seçilmiş hastalarda ve klinik koşullarda hayat kurtaran bir tedavidir. Çalışmamızda en sık İVİg kullanılan ve mortalitenin en fazla olduğu hastalık grubu sepsis olarak bulunmuştur. Endikasyon dışı hastalıklarda, özelikle sepsiste, alternatif tedaviler ile İVİg kullanımı azaltılabilir.

🔖

Cite This Article

ATAKUL, G., CEYLAN, G., AĞIN, H., SANDAL, Ö. S., SARI, F. (2022). Assessment of Intravenous Immunoglobulin Indications in Pediatric Intensive Care. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, Cilt: 12 - Sayı: 1, 6–12. https://ajindex.com/articles/557595

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Johnston SL, Hollingsworth R. Immunoglobulin therapy. Clin Med (Lond). 2016;16(6):576-9. doi: 10.7861/clinmedicine.16-6-576
  2. Zülfikar B, Koç B. Use of intravenous immunoglobulin in pediatric practice. Turk Pediatri Ars. 2014;49(4):282-8. doi: 10.5152/tpa.2014.2212
  3. Prasad AN, Chaudhary S. Intravenous immunoglobulin in pediatrics: A review. Med J Armed Forces India. 2014;70(3):277-80. doi: 10.1016/j.mjafi.2013.05.011
  4. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, D Kazatchkine M, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27(3):233-45. doi: 10.1007/s10875-007-9088-9
  5. Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228-31. doi: 10.1016/s0140-6736(81)92400-4
  6. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-33. doi: 10.1146/annurev.immunol.26.021607.090232
  7. Simon HU, Späth PJ. IVIG--mechanisms of action. Allergy. 2003;58(7):543-52. doi: 10.1034/j.1398-9995.2003.00239.x
  8. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255(Suppl 3):3-6. doi: 10.1007/s00415-008-3002-0
  9. Leong H, Stachnik J, Bonk ME, Matuszewski KA. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm. 2008;65(19):1815-24. doi: 10.2146/ajhp070582
  10. Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci. 2005;1051:743-78. doi: 10.1196/annals.1361.118
  11. Yu DQ, Wang Y, Ma GZ, Xu RH, Cai ZX, Ni CM, et al. Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: A retrospective study. Exp Ther Med. 2014;7(1):97-102. doi: 10.3892/etm.2013.1372
  12. Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, A Lopez Chiriboga S, et al. Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Ann Neurol. 2020;87(2):313-23. doi: 10.1002/ana.25655
  13. Iro MA, Martin NG, Absoud M, Pollard AJ. Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev. 2017;10(10):CD011367. doi: 10.1002/14651858.CD011367.pub2
  14. Toh CC, Islahudin F, Ali A, Shah NM. Intravenous immunoglobulin therapy among pediatric patients: labe